Anders Lonner - Karo Pharma Insider

KARBF -- USA Stock  

USD 4.00  0.45  12.68%

Mr. Anders Lonner was Executive Chairman of the Board of Directors of Karo Pharma AB since February 4, 2015. He has previously been Independent Chairman of the Board since May 8, 2014. He holds MS in Political Science degree. He was previously Chief Executive Officer and President for Meda AB and had before then been CEO for Astra Lakemedel with responsibility for, among other things, Astras Nordic subsidiaries, CEO in Karo Bio AB and President of Lakemedelsforeningen. He is Advisor for EQT. In 2014 he was nominated Honorary Doctor of Medicine at Karolinska Institutet.
Age: 72  Chairman Since 2015      
46 1 03 30 23 10

Management Efficiency

The company has return on total asset (ROA) of 2.94 % which means that it generated profit of $2.94 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of 2.7 % meaning that it generated $2.7 on every $100 dollars invested by stockholders.
The company has accumulated 193.08 M in total debt with debt to equity ratio (D/E) of 91.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karo Pharma AB has Current Ratio of 2.3 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 6 records


John ThompsonMicrosoft Corporation
Roberto SampedroEcopetrol S A
Jeffrey BezosAmazon
Eric SchmidtAlphabet

Entity Summary

Karo Pharma AB , a healthcare company, develops and markets products for pharmacies and the health care sectors in Sweden, Norway, Denmark, and Finland. Karo Pharma AB was founded in 1987 and is headquartered in Stockholm, Sweden. Karo Pharma is traded on OTC Market in USA.Karo Pharma AB (KARBF) is traded on OTC Market in USA. It is located in Nybrokajen 7 and employs 80 people.

Karo Pharma AB Leadership Team

PerAnders Johansson, Independent Director
Jean Lycke, Director
Per Johansson, Member of the Board
Peter Blom, CEO
Henrik Palm, CFO
Anders Lonner, Chairman of the Board
Marianne Hamilton, Director
Maria Sjoberg, Vice President Chief Scientific Officer, responsible for Preclinical Research and Development
Hakan Astrom, Director
Thomas Kraft, Country Manager Norway
Goran Wessman, Director
Bo Carlsson, Member of the Board, Employee Representative
Thomas Hedner, Director

Stock Performance Indicators

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Price Exposure Probability

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.